Dog dewormer has not been proven to cure cancer in humans. The drug in question, fenbendazole, does kill cancer cells in lab dishes and shrink tumors in mice, and a handful of people have reported dramatic remissions while taking it. But no controlled clinical trial has ever tested whether fenbendazole works as a cancer treatment in people, which means there is currently no reliable evidence that it does.
That said, the story is more nuanced than a simple “no.” Here’s what the science actually shows, what the risks are, and why the gap between lab results and a proven cure matters so much.
Where the Idea Came From
The claim went viral in 2019 when a man named Joe Tippens shared on YouTube that he had completely cured his metastatic lung cancer by taking fenbendazole, the active ingredient in common dog dewormers like Panacur. His daily regimen also included curcumin (600 mg), cannabidiol oil (25 mg), and fenbendazole (222 mg taken three days on, four days off). Tippens was also receiving conventional cancer treatment at the time, a detail that often gets lost in retellings.
The story spread rapidly, particularly in South Korea, where surveys found significant numbers of cancer patients began self-administering veterinary deworming drugs. Since then, scattered case reports and a growing body of lab research have kept interest alive.
What Fenbendazole Does to Cancer Cells
Fenbendazole was designed to kill parasitic worms by destroying their internal scaffolding, a network of protein tubes called microtubules. Cancer cells also depend heavily on microtubules to divide and spread. In fact, some of the most widely used chemotherapy drugs work by targeting this same structure. Fenbendazole binds to the same site on these proteins, though with weaker affinity than dedicated cancer drugs or even other known microtubule disruptors.
Lab studies published in Scientific Reports showed that fenbendazole does more than just interfere with cell structure. It also starves cancer cells by blocking their ability to absorb glucose. Cancer cells are notorious for consuming enormous amounts of sugar to fuel their rapid growth. Fenbendazole reduced the production of glucose transporters on the cell surface and inhibited a key enzyme that cancer cells rely on to process that sugar. Computer modeling suggested fenbendazole may physically mimic glucose, plugging into the enzyme’s active site and shutting it down.
A 2025 study in Frontiers in Pharmacology added another piece: fenbendazole triggered a type of inflammatory cell death called pyroptosis in breast cancer cells, causing them to swell, form pores, and burst. In mice, this translated to significant tumor shrinkage at medium doses, comparable to cisplatin, a standard chemotherapy drug. Notably, the drug showed negligible toxicity to normal breast cells in the same experiments.
The Gap Between Lab Results and a Cure
Killing cancer cells in a dish is the easiest bar to clear in cancer research. Bleach kills cancer cells in a dish. The real question is whether a drug can reach tumors inside a living human body, at high enough concentrations, for long enough, without causing unacceptable harm. Fenbendazole faces real challenges on each of these fronts.
The drug was engineered specifically to be poorly absorbed from the gut, because it only needs to work inside an animal’s intestines to kill worms. In humans, this means very little of an oral dose reaches the bloodstream, and even less reaches distant tumors. The concentrations that killed cancer cells in lab studies were in the micromolar range, and it’s unclear whether oral dosing in humans can reliably achieve those levels in tumor tissue.
Fenbendazole is not approved by the FDA or the European Medicines Agency for any use in humans. Because of this, its behavior in the human body, including how it’s metabolized and how it interacts with other drugs, has never been formally studied. There are no standardized doses, no established safety profiles, and no quality controls on products people are buying online or at pet stores.
Human Evidence So Far
The clinical evidence is limited to case reports, not trials. A 2025 case series published in a peer-reviewed journal described three patients with advanced cancers (breast, prostate, and melanoma) who added fenbendazole to their treatment plans while declining chemotherapy. Two achieved complete remission and one achieved near-complete remission, with follow-up periods ranging from 11 months to nearly three years. All three tolerated the drug without reported side effects.
The authors themselves emphasized that these are anecdotal observations. All three patients were receiving other therapies alongside fenbendazole, making it impossible to attribute the remissions to the dewormer alone. Spontaneous remissions, while rare, do occur. And case reports inherently suffer from selection bias: people whose cancer progressed or worsened on fenbendazole are far less likely to be written up or shared online.
A related drug called mebendazole, which is approved for human use against parasitic infections, has a slightly longer track record in case reports. In one, a patient with metastatic adrenal cancer saw his liver tumors shrink and remain stable for 19 months on mebendazole. In another, a colon cancer patient experienced near-complete remission of lung and lymph node metastases after six weeks. Several clinical trials of mebendazole for cancer have been registered, though published results from those trials are still pending.
Safety Risks Are Real
Fenbendazole is often described as “safe” because it has been used in animals for decades. But veterinary safety data doesn’t transfer directly to humans, especially at the higher doses or longer durations that cancer patients tend to use.
In 2024, a medical journal reported the first confirmed case of severe liver injury caused by fenbendazole. A 67-year-old woman who had been self-administering the drug developed jaundice, nausea, dark urine, and a painful rash. Her liver enzymes climbed to more than 50 times the normal level, and bilirubin (a marker of liver damage) peaked at 24 mg/dL, roughly 20 times normal. A liver biopsy showed broad zones of tissue death. She met criteria for severe drug-induced liver injury.
An earlier case of milder liver damage had also been linked to fenbendazole in a lung cancer patient, though that case had potential confounders from immunotherapy. These reports don’t mean everyone who takes fenbendazole will develop liver problems, but they confirm the drug can cause serious harm in some people, and there’s currently no way to predict who is at risk.
Why Conventional Medicine Hasn’t Adopted It
The oncology establishment hasn’t rejected fenbendazole out of hand. Researchers at major institutions have published the lab and animal data described above, and many have called for proper clinical trials. The problem is that those trials haven’t happened yet, and without them, no one can say whether fenbendazole helps, harms, or does nothing for cancer patients in the real world.
Clinical trials exist precisely because the history of cancer research is full of compounds that looked extraordinary in the lab and failed in humans. The journey from “kills cancer cells in a dish” to “reliably treats cancer in people” has a failure rate above 95%. Fenbendazole may eventually beat those odds, but right now it’s still in the early stages of that process. Conventional medical institutions and oncologists do not currently recommend it for cancer treatment.
People who choose to self-administer fenbendazole are essentially running an uncontrolled experiment on themselves, without dosing guidance, without monitoring for liver toxicity, and without knowing whether the drug might interfere with any conventional treatments they’re also receiving. The fact that fenbendazole works on microtubules, the same target as several chemotherapy drugs, raises a particular concern: it could theoretically compete with or alter the effectiveness of those treatments in unpredictable ways.